César L Boguszewski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1093967/publications.pdf

Version: 2024-02-01

125 4,055 32 papers citations h-index

149 149 3863
all docs docs citations times ranked citing authors

56

g-index

#	Article	IF	CITATIONS
1	Acromegaly and pregnancy: a systematic review and meta-analysis. Pituitary, 2022, 25, 352-362.	2.9	5
2	Thyroid and Breast Cancer in 2 Sisters With Monoallelic Mutations in the Ataxia Telangiectasia Mutated (<i>ATM</i>) Gene. Journal of the Endocrine Society, 2022, 6, bvac026.	0.2	5
3	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	3.7	42
4	Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO). Archives of Endocrinology and Metabolism, 2022, , .	0.6	6
5	Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing $\hat{a} \in \mathbb{N}$ disease. Pituitary, 2022, , .	2.9	1
6	Prevalence of sarcopenia in women at stable weight phase after Roux-en-Y gastric bypass. Archives of Endocrinology and Metabolism, 2022, , .	0.6	1
7	Personality type, eating behaviour and suicide risk in women in treatment for obesity. Eating and Weight Disorders, 2021, 26, 547-554.	2.5	1
8	Individual sensitivity to growth hormone replacement in adults. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 117-124.	5 . 7	9
9	Multidisciplinary Approach for Weight Regainâ€"how to Manage this Challenging Condition: an Expert Review. Obesity Surgery, 2021, 31, 1290-1303.	2.1	37
10	Prevalence of thyroid cancer in patients with acromegaly and non-growth hormone secreting pituitary adenomas: A prospective cross-sectional study. Growth Hormone and IGF Research, 2021, 56, 101378.	1.1	4
11	Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs. Frontiers in Endocrinology, 2021, 12, 637209.	3.5	38
12	Management of hypopituitarism: a perspective from the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2021, 65, 212-230.	0.6	5
13	Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2047-2056.	3. 6	27
14	Medical therapy in severe hypercortisolism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101487.	4.7	8
15	GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil. Endocrine, 2021, 74, 146-154.	2.3	3
16	Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4734-e4745.	3.6	10
17	Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors—a review of research and clinical practice. Pituitary, 2021, 24, 810-827.	2.9	17
18	Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 732240.	3.5	13

#	Article	IF	CITATIONS
19	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology, the, 2021, 9, 847-875.	11.4	315
20	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	3.6	207
21	A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary, 2020, 23, 120-128.	2.9	23
22	From dwarves to giants: South American's contribution to the history of growth hormone and related disorders. Growth Hormone and IGF Research, 2020, 50, 48-56.	1.1	4
23	Editorial: Health-Related Complications of Acromegaly. Frontiers in Endocrinology, 2020, 11, 496.	3.5	1
24	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
25	Metabolic syndrome and its components in adult hypopituitary patients. Pituitary, 2020, 23, 409-416.	2.9	11
26	Relations between serum magnesium and calcium levels and body composition and metabolic parameters in women with fibromyalgia. Advances in Rheumatology, 2020, 60, 18.	1.7	8
27	Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem. Endocrine Practice, 2020, 26, 340-353.	2.1	21
28	Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission. Endocrine, 2020, 68, 182-191.	2.3	10
29	Fertility issues in aggressive pituitary tumors. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 225-233.	5.7	8
30	Acromegaly: â€~You must know it to think of it'. European Journal of Endocrinology, 2020, 183, C1-C4.	3.7	5
31	What's in a name? What we call growth hormone is much more than just a growth-related peptide. Archives of Endocrinology and Metabolism, 2020, 63, 546-548.	0.6	1
32	Brazilian multicenter study on pegvisomant treatment in acromegaly. Archives of Endocrinology and Metabolism, 2019, 63, 328-336.	0.6	16
33	Body composition and nutritional and metabolic parameters in postmenopausal women sufficient, insufficient and deficient in vitamin D. Archives of Endocrinology and Metabolism, 2019, 63, 265-271.	0.6	1
34	Growth Hormone's Links to Cancer. Endocrine Reviews, 2019, 40, 558-574.	20.1	80
35	Management of pituitary incidentaloma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101268.	4.7	21
36	Relation between magnesium and calcium and parameters of pain, quality of life and depression in women with fibromyalgia. Advances in Rheumatology, 2019, 59, 55.	1.7	16

#	Article	IF	Citations
37	MECHANISMS OF ENDOCRINE DISEASE: Sarcopenia in endocrine and non-endocrine disorders. European Journal of Endocrinology, 2019, 180, R185-R199.	3.7	18
38	Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. European Journal of Endocrinology, 2019, 181, L5-L6.	3.7	18
39	Sarcopenia in heart failure with reduced ejection fraction. American Journal of Cardiovascular Disease, 2019, 9, 116-126.	0.5	2
40	Body composition and sarcopenia in patients with chronic obstructive pulmonary disease. Endocrine, 2018, 60, 95-102.	2.3	34
41	Different Cerebellar Ataxia Phenotypes Associated with Mutations of the PNPLA6 Gene in Brazilian Patients with Recessive Ataxias. Cerebellum, 2018, 17, 380-385.	2.5	20
42	Two threshold levels of vitamin D and the prevalence of comorbidities in outpatients of a tertiary hospital. Osteoporosis International, 2018, 29, 433-440.	3.1	1
43	Association between undercarboxylated osteocalcin, bone mineral density, and metabolic parameters in postmenopausal women. Archives of Endocrinology and Metabolism, 2018, 62, 446-451.	0.6	7
44	Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. European Journal of Endocrinology, 2018, 179, 59-71.	3.7	116
45	Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2018, 62, 236-263.	0.6	69
46	Bone mineral density and vertebral fractures and their relationship with pulmonary dysfunction in patients with chronic obstructive pulmonary disease. Osteoporosis International, 2018, 29, 2537-2543.	3.1	15
47	A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2018, 62, 87-105.	0.6	3
48	Novel <i>SUZ12</i> mutations in Weaverâ€like syndrome. Clinical Genetics, 2018, 94, 461-466.	2.0	36
49	Glucagon stimulation test: has its time come?. Endocrine, 2017, 57, 361-363.	2.3	7
50	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary, 2017, 20, 489-498.	2.9	233
51	MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism. European Journal of Endocrinology, 2017, 177, R309-R321.	3.7	11
52	Fragility Fracture Incidence in Chronic Obstructive Pulmonary Disease (COPD) Patients Associates With Nanoporosity, Mineral/Matrix Ratio, and Pyridinoline Content at Actively Bone-Forming Trabecular Surfaces. Journal of Bone and Mineral Research, 2017, 32, 165-171.	2.8	10
53	Update on GH therapy in adults. F1000Research, 2017, 6, 2017.	1.6	20
54	Serum levels of leptin and adiponectin and clinical parameters in women with fibromyalgia and overweight/obesity. Archives of Endocrinology and Metabolism, 2017, 61, 249-256.	0.6	19

#	Article	IF	CITATIONS
55	Endoscopic versus microscopic transsphenoidal surgery in the treatment of pituitary tumors: systematic review and meta-analysis of randomized and non-randomized controlled trials. Archives of Endocrinology and Metabolism, 2016, 60, 411-419.	0.6	18
56	Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing's disease in Brazil. Archives of Endocrinology and Metabolism, 2016, 60, 267-286.	0.6	14
57	A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Archives of Endocrinology and Metabolism, 2016, 60, 374-390.	0.6	20
58	MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited. European Journal of Endocrinology, 2016, 175, R147-R156.	3.7	66
59	Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary, 2016, 19, 448-457.	2.9	108
60	Chronic l-menthol-induced browning of white adipose tissue hypothesis: A putative therapeutic regime for combating obesity and improving metabolic health. Medical Hypotheses, 2016, 93, 21-26.	1.5	25
61	Growth hormone, insulin-like growth factor system and carcinogenesis. Endokrynologia Polska, 2016, 67, 414-26.	1.0	17
62	Sarcopenia in COPD: relationship with COPD severity and prognosis. Jornal Brasileiro De Pneumologia, 2015, 41, 415-421.	0.7	80
63	In the land of giants: the legacy of José Dantas de Souza Leite. Arquivos De Neuro-Psiquiatria, 2015, 73, 630-632.	0.8	2
64	Subtle changes in bone mineralization density distribution in most severely affected patients with chronic obstructive pulmonary disease. Bone, 2015, 79, 1-7.	2.9	8
65	Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E531-E541.	3.6	145
66	Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary, 2015, 18, 500-508.	2.9	36
67	Whole Exome Sequencing of Extreme Morbid Obesity Patients: Translational Implications for Obesity and Related Disorders. Genes, 2014, 5, 709-725.	2.4	19
68	Acromegaly and pregnancy: a prospective study. European Journal of Endocrinology, 2014, 170, 301-310.	3.7	39
69	Osteocalcin, energy and glucose metabolism. Arquivos Brasileiros De Endocrinologia E Metabologia, 2014, 58, 444-451.	1.3	38
70	Vitamin D deficiency in children and adolescents submitted to hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 126-131.	0.7	18
71	A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. International Journal of Obesity, 2014, 38, 1097-1103.	3.4	41
72	Bone mineral density, vitamin D, and nutritional status of children submitted to hematopoietic stem cell transplantation. Nutrition, 2014, 30, 654-659.	2.4	27

#	Article	IF	Citations
73	Extracellular Water and Blood Pressure in Adults with Growth Hormone (GH) Deficiency: A Genotype-Phenotype Association Study. PLoS ONE, 2014, 9, e105754.	2.5	7
74	Endocrine Hypertension., 2014,, 127-143.		0
75	Are patients in remission from Cushing's syndrome mentally healthy?. Clinical Endocrinology, 2013, 79, 615-616.	2.4	O
76	Postoperative structural complications after microscopic transsphenoidal surgery of GH secreting pituitary adenomas. Brazilian Neurosurgery, 2013, 32, 221-224.	0.1	1
77	Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period. Arquivos Brasileiros De Endocrinologia E Metabologia, 2013, 57, 709-716.	1.3	6
78	Genotypes associated with lipid metabolism contribute to differences in serum lipid profile of GH-deficient adults before and after GH replacement therapy. European Journal of Endocrinology, 2012, 167, 353-362.	3.7	18
79	Evidence for Higher Success Rates and Successful Treatment Earlier in Graves' Disease with Higher Radioactive Iodine Doses. Thyroid, 2012, 22, 991-995.	4.5	22
80	Comparison of two dose regimens of growth hormone (GH) with different target IGF-1 levels on glucose metabolism, lipid profile, cardiovascular function and anthropometric parameters in gh-deficient adults. Growth Hormone and IGF Research, 2012, 22, 116-121.	1.1	3
81	Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma. Arquivos Brasileiros De Endocrinologia E Metabologia, 2012, 56, 507-512.	1.3	17
82	A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary, 2012, 15, 44-49.	2.9	53
83	Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary, 2011, 14, 259-265.	2.9	95
84	Management of prolactinomas in Brazil: an electronic survey. Pituitary, 2010, 13, 199-206.	2.9	11
85	Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. Journal of Bone and Mineral Research, 2010, 25, 1931-1940.	2.8	45
86	Application of genetic testing to define the surgical approach in a sporadic case of multiple endocrine neoplasia type 1. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 705-710.	1.3	4
87	The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): Four-stage translation and validation. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 833-841.	1.3	6
88	Models to predict changes in serum IGF1 and body composition in response to GH replacement therapy in GH-deficient adults. European Journal of Endocrinology, 2010, 162, 869-878.	3.7	17
89	Neuroendocrine body weight regulation: integration between fat tissue, gastrointestinal tract, and the brain. Endokrynologia Polska, 2010, 61, 194-206.	1.0	26
90	Performance of computed tomographic colonography for the screening of colorectal polyp in acromegalic patients: a prospective study. Arquivos De Gastroenterologia, 2009, 46, 90-96.	0.8	6

#	Article	IF	Citations
91	Influence of the Exon 3-Deleted/Full-Length Growth Hormone (GH) Receptor Polymorphism on the Response to GH Replacement Therapy in Adults with Severe GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 639-644.	3.6	32
92	Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporosis International, 2009, 20, 1881-1887.	3.1	91
93	Bone Mineral Density, Lean Body Mass, Calcium and Vitamin D Intake In Children and Adolescents After Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 79-80.	2.0	9
94	Decrease in leptin production by the adipose tissue in obesity associated with severe metabolic syndrome. Arquivos Brasileiros De Endocrinologia E Metabologia, 2009, 53, 1088-1095.	1.3	33
95	Efeitos end \tilde{A}^3 crinos e metab \tilde{A}^3 licos dos antiepil \tilde{A} ©pticos. Journal of Epilepsy and Clinical Neurophysiology, 2008, 14, 32-38.	0.1	O
96	Insulin-Like Growth Factor-1, Leptin, Body Composition, and Clinical Status Interactions in Children with Cystic Fibrosis. Hormone Research in Paediatrics, 2007, 67, 250-256.	1.8	22
97	Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Brazilian Journal of Medical and Biological Research, 2007, 40, 1661-1670.	1.5	29
98	Bone density and bone turnover markers in patients with epilepsy on chronic antiepileptic drug therapy. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 466-471.	1.3	17
99	One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. European Journal of Endocrinology, 2005, 152, 67-75.	3.7	51
100	Circulating non-22 kDa growth hormone isoforms after a repeated GHRH stimulus in normal subjects. Growth Hormone and IGF Research, 2005, 15, 123-129.	1.1	3
101	Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arquivos De Neuro-Psiquiatria, 2004, 62, 940-948.	0.8	68
102	Molecular heterogeneity of human GH: From basic research to clinical implications. Journal of Endocrinological Investigation, 2003, 26, 274-288.	3.3	24
103	The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms. Growth Hormone and IGF Research, 2003, 13, 1-7.	1.1	3
104	The Cerebrospinal Fluid/Serum Leptin Ratio during Pharmacological Therapy for Obesity. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1621-1626.	3.6	33
105	O Laboratório no Diagnóstico e Seguimento da Acromegalia. Arquivos Brasileiros De Endocrinologia E Metabologia, 2002, 46, 34-44.	1.3	4
106	Growth hormone (GH) replacement therapy in GH-deficient women during pregnancy. Clinical Endocrinology, 2002, 57, 235-239.	2.4	33
107	Changes in Non-22-Kilodalton (kDa) Isoforms of Growth Hormone (GH) after Administration of 22-kDa Recombinant Human GH in Trained Adult Males1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1731-1737.	3.6	64
108	The Response of Molecular Isoforms of Growth Hormone to Acute Exercise in Trained Adult Males 1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 200-206.	3.6	75

#	Article	IF	CITATIONS
109	The Response of Molecular Isoforms of Growth Hormone to Acute Exercise in Trained Adult Males. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 200-206.	3.6	66
110	Changes in Non-22-Kilodalton (kDa) Isoforms of Growth Hormone (GH) after Administration of 22-kDa Recombinant Human GH in Trained Adult Males. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1731-1737.	3.6	60
111	Genética molecular do eixo GH-IGF1. Arquivos Brasileiros De Endocrinologia E Metabologia, 2001, 45, 5-14.	1.3	8
112	Concomitant Presentation of Hashimoto's Thyroiditis and Maltoma of the Thyroid in a Twenty-Year-Old Man with a Rapidly Growing Mass in the Neck. Thyroid, 2000, 10, 833-835.	4.5	6
113	Growth hormone isoforms in newborns and postpartum women. European Journal of Endocrinology, 2000, 142, 353-358.	3.7	11
114	Cloning of Two Novel Growth Hormone Transcripts Expressed in Human Placenta. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2878-2885.	3.6	15
115	Cloning of Two Novel Growth Hormone Transcripts Expressed in Human Placenta1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2878-2885.	3.6	47
116	Circulating non-22 kDa growth hormone isoforms in healthy children of normal stature: relation to height, body mass and pubertal development. European Journal of Endocrinology, 1997, 137, 246-253.	3.7	18
117	Increased Proportion of Circulating Non-22-Kilodalton Growth Hormone Isoforms in Short Children: A Possible Mechanism for Growth Failure1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2944-2949.	3.6	39
118	Circulating Non-22-Kilodalton Growth Hormone Isoforms in Acromegalic Men before and after Transsphenoidal Surgery 1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1516-1521.	3.6	29
119	Adrenal response to corticotrophin and testosterone during long-term therapy with itraconazole in patients with chromoblastomycosis. Journal of Antimicrobial Chemotherapy, 1997, 40, 899-902.	3.0	21
120	Mechanisms of Growth Failure in Non-Growth-Hormone Deficient Children of Short Stature. Hormone Research, 1997, 48, 19-22.	1.8	6
121	Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clinical Chemistry, 1997, 43, 950-956.	3.2	98
122	Circulating Non-22-Kilodalton Growth Hormone Isoforms in Acromegalic Men before and after Transsphenoidal Surgery. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1516-1521.	3.6	26
123	Increased Proportion of Circulating Non-22-Kilodalton Growth Hormone Isoforms in Short Children: A Possible Mechanism for Growth Failure. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2944-2949.	3.6	38
124	22-kD Growth hormone exclusion assay: a new approach to measurement of non-22-kD growth hormone isoforms in human blood. European Journal of Endocrinology, 1996, 135, 573-582.	3.7	44
125	Acromegaly and cancer. Endocrine Abstracts, 0, , .	0.0	0